Summary
In a double-blind quadruple cross-over study the effect of a newα-glucosidase inhibitor (BAY g 5421) on postprandial blood glucose, serum insulin, and serum triglyceride increases was tested in 24 male healthy volunteers. They received before a standardized breakfast 50, 100, or 200 mg of BAY g 5421 or a placebo per os. The dose-time-response relationships were calculated and the drug tolerance was assessed.
There was a statistically significant inhibition of the postprandial increases of the blood glucose, serum insulin, and triglyceride values. Further analysis showed no dose-dependent effect of the drug on the blood glucose values, whereas the serum insulin and triglyceride values were affected in a dosedependent fashion. The maximal inhibitory effect on the serum insulin levels occurred 69 min after breakfast and on the serum triglyceride levels 104 min after breakfast.
One hundred and 200 mg of BAY g 5421 were equally inhibitory-effective on the serum insulin levels, whereas the highest dose used was markedly more effective on serum triglyceride values than lower doses.
Based on these results, a dosage of 100–200 mg of BAY g 5421/meal is recommended for clinical trials in metabolic diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bryce, G. R., Carter, M. W.: MAD—The analysis of variance in unbalanced designs—a software package. In: Compstat 1974, Proc. computational statistics, pp. 447–456. Wien: Physica Verlag 1974
Caspary, W. F.: Sucrose malabsorption in man after ingestion ofα-glucoside-hydrolase inhibitor. Lancet1978 I, 1231–1233
Douglas, J.: Program BMD 2PR “Stepwise Regression”; Biomed. computer programs, P-Series. Univ. Calif. Press 1977
Eggstein, M., Kreutz, F. H.: Eine neue Bestimmung der Neutralfette im Blutserum und Gewebe. Klin. Wschr.44, 262 (1966)
Hillebrand, I., Boehme, K., Frank, G., Fink, H., Berchtold, P.: Effects of the glucoside-hydrolase inhibitor BAY g 5421 on postprandial blood glucose, serum insulin, and triglyceride levels: Dose-time relationships in man. Diabetologia15, 239 (1978)
Hillebrand, I., Boehme, K., Frank, G., Fink, H., Berchtold, P.: The effects of theα-glucosidase inhibitor BAY g 5421 on meal-stimulated blood glucose, serum insulin, and triglyceride levels in man. Res. Exp. Med.175, 81–86 (1979)
Huggett, A. St., Nixon, D. A.: Use of glucose oxidase, peroxidase and O-Dianisidine in determination of blood and urinary glucose. Lancet273, 363–370 (1957)
Melani, F., Ditschuneit, F., Bartelt, K. M., Friedrich, H., Pfeiffer, E. F.: Über die radioimmunologische Bestimmung von Insulin im Blut. Klin. Wschr.43, 1000–1007 (1965)
Puls, W., Keup, U., Krause, H. P., Thomas, G., Hoffmeister, F.: Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinemia. Naturwissenschaften64, 536 (1977)
Schmidt, D. D., Frommer, W., Junge, B., Müller, L., Wingender, W., Truscheit, E., Schäfer, D.:α-glucosidase inhibitors. New complex oligosaccharides of microbial origin. Naturwissenschaften64, 535–536 (1977)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hillebrand, I., Boehme, K., Frank, G. et al. The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: Dose-time-response relationships in man. Res. Exp. Med. 175, 87–94 (1979). https://doi.org/10.1007/BF01851237
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01851237